

# The Molecular Basis of Prostate Cancer and Targeting Therapies

by Prof. Serge Jurasunas

## References

1. Miller DC, et al. Prostate carcinoma, presentation, diagnosis and staging: and update from the Nat Cancer Data Base. *Cancer*. Sept 2003;98(6):1169-78.
2. Morris SY. Prostate cancer: prognosis – Life expectancy for bone metastases. *Healthline*. 28 July 2004.
3. Hankey BF, et al. Cancer surveillance series: interpreting trends in prostate cancer – part I. Evidence of the effects of screening in recent prostate cancer incidence, mortality and survival rates: *J Nat Cancer Inst*. July 16,1999;91(12):1017-24.
4. Rennie PS, Nelson CC. Epigenetic mechanisms for progression of prostate cancer. *Cancer Metastasis Rev*. 1998;17(4) 401-9.
5. Naumov GN, et al. Role of angiogenesis in human tumor dormancy. *Animals models of the angiogenic switch*. *Cell Cycle*. 2006;5(16):1179-1787.
6. Zarmarron BF, Chen W. Dual roles of immune cells and their factors in cancer development and progression. *Int J Sci*. 2011;7(5):651-658.
7. McKenzies S, Kyprianou N. Apoptosis evasion: The role of survival pathways in prostate cancer progression and therapeutic resistance. *J Cell Biochem*. 2006;97(1): 18.
8. Fleshner NE, Klotz LH. Diet, androgens, oxidative stress and prostate cancer susceptibility. *Cancer Metastasis Rev*. 1994;17:325-330.
9. Petros JA, et al. MtDNA mutations increase tumorigenicity in prostate cancer. *Natl Acad Sci (USA)* 2005;102:719-724.
10. Collins K, et al. The cell cycle and cancer. *Nat Acad Sci (USA)*. 1997;94 (7):2776-2778.
11. Fernald K, Kurokawa M. Evasion of apoptosis a main hallmark of cancer. *Trends Cell Biol*. Dec.23, 2013; (12): 620-33.
12. Nazanin S, et al. Dormancy in solid tumors: implications in prostate cancer. *Cancer Metastasis Rev*. 2013 Dec 32(0).
13. Douma S, et al. Suppression of anoikis and induction of metastases by the neurotrophic receptor TrkB. *Nature*. 2004;430:1034-1039.
14. McKenzie S, Kyprianou N. Apoptosis evasion: The role of survival pathways in prostate cancer progression and therapeutic resistance. *J Cell Biochem*. 2006; 97(1):18.
15. Navone NM, et al. P53 protein accumulation and gene mutation in the progression of human prostate carcinoma. *J Nat Cancer Inst*. 1993;85(29):1657-1659.
16. Haupt S, et al. Apoptosis-The P53 network. *J Cell Science*. 2003;116:4077-4085.
17. Amati B, Land H. C-Myc – Max – Mad a transcription factor network controlling cell cycle progression, differentiation and death. *Curr Opin Gene Dev*. 1994;4:102-108.
18. Van Den Berg C, et al. DNA sequence amplification in human prostate cancer identified by chromosome microdissection. Potential prognostic implications. *Clin Cancer Res*. 1995;111:18.
19. Buttyan R, et al. Enhanced expression of the C-Myc protooncogene in high grade human prostate cancer. *Prostate*. 1987; 11(4): 327-37.
20. Heman MT, et al. Evasion of the P53 tumor surveillance network by tumor derived C-Myc mutants. *Nature*. 2005;436-807.
21. Ho JS, et al. P53 –dependent transcriptional repression of C-Myc is required for G1 cell cycle arrest. *Mol Cell Biol*. 2005; 25.
22. Song MS, et al. The function and regulation of the PTEN tumor suppressor. *Nat Rev Mol Cell Biol*. 2012;13:283-296.
23. Cairns P, et al. Frequent inactivation of PTEN in primary prostate cancer. *Cancer Res*. 1997;57:4997-5000.
24. Alimonti A, et al. Subtle variations in PTEN dose determine cancer susceptibility. *Nat Genet*. 2010;42:454-458.
25. Fresno Vara JA, et al. P13K/Akt signaling pathway and cancer. *Cancer Treat Rev*. 2004 Apr; 30(2):193-204.
26. Dillon LM, Miller TW. Therapeutic targeting of cancers with loss of PTEN function. *Curr Drug Targets*. 2014 Jan;15(1):65-74.
27. Freeman DJ, et al. PTEN tumor suppressor regulates P53 protein levels and activity through phosphatase – dependent and independent mechanisms. *Cancer Cell*. 2003;3:117-130.
28. Mayo LD, et al. PTEN protects P53 from MDM2 and sensitizes cancer cells to chemotherapy. *J Biol Chem*. 2002;277:5484-5489.
29. Piccoli S. P53 regulation orchestrate the TGF $\beta$  response. *Cell*. 2008;133(5):768-769.
30. Wikstrom P, et al. Transforming growth factor beta is associated with angiogenesis in metastasis and poor clinical outcome in prostate cancer. *The Prostate*. 15 September 1998.
31. Derynck R, et al. TGF $\beta$  signaling in tumor suppression in cancer progression. *Nature Genetics*. 2001;29:117-129.
32. Jones E, et al. Targeting TGF $\beta$  in prostate cancer: therapeutic possibility during tumor progression. *Expert Opin Ther Targets*. 2008;13(2):227-234.
33. Ismail HA, et al. Expression of NF-kappaB in prostate cancer lymph node metastases. *Prostate*. 2004;58(3): 308-313.
34. Ryan KM, et al. Role of NF-kappaB in P53-mediated programmed cell death. *Nature*. 2000;404:892-897.
35. Ravi R, et al. P53-mediated repression of nuclear factor Kappa B via the transcriptional integrator P300. *Cancer Res*. 1998;58:4531-4536.
36. Huang S, et al. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion and metastases. *Oncogene*. 2001;20 (31): 4188-4197.

37. Navone NM, et al. P53 protein accumulation and gene mutation in the progression of human prostate carcinoma. *J Natl Cancer Inst.* 1993;85(20):1657-1669.
38. Pisters LL, et al. Evidence that transfer of functional P53 protein results in the increased apoptosis in prostate cancer. *Clin Cancer Res.* 2004;10(8): 2587-2593.
39. Jurasunas S, Taylor OG. How to target mutant P53 in a case of multiple cancer recurrence. *Townsend Letter.* August/Sept 2010.
40. Jurasunas S. The P53 tumor suppressor gene: understanding P53-based anticancer therapies utilizing dietary agents. *Townsend Letter.* August/Sept 2015; 67-73.
41. Gross A, et al. BCL2 family members and the mitochondria in apoptosis. *Genes Dev.* 1999;13:1899-1911.
42. Hockenbery D, et al. BCL2 is an inner mitochondrial membrane protein that blocks programmed cell death. *Nature.* 1990 Nov 22;348:334-6.
43. Crompton M. The mitochondrial permeability transition pore and its role in cell death. *Biochem J.* 1999;341:200-249.
44. Chipuk T, et al. Direct activation of BAX by P53 mediates mitochondrial permeabilization and apoptosis. *Science.* 2004;303:1100-1014.
45. Schuler M, et al. P53 induces apoptosis by caspase activation through mitochondrial cytochrome C release. *J Biol. Chem.* 2000;275: 7337-7342.
46. Kuwana T, et al. Apoptosis induction by caspases 8 is amplified through the mitochondrial release of cytochrome C. *J Biol Chemistry.* 1998;273:16589-16594.
47. Hockenberry DM, et al. BCL-2 is an inner mitochondrial membrane protein that blocks programmed cell death. *Nature (London).* 1990;548:334-336.
48. Lin Y, et al. Up regulation of BCL2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen independent growth stage. *Cell Res.* 2007;17:531-536.
49. Raffo AJ, et al. Overexpression of BCL-2 protects prostate cancer from apoptosis in-vitro and confers resistance to androgen depletion in-vivo. *Cancer Res.* Oct 1, 1995;55:44-38.
50. Lieberman D, Reed JC. Tumor suppressor P53 is a regulator of Bcl2 and Bax in gene expression in-vitro and in-vivo. *Oncogene.* 1994;1799-1805.
51. Schenr DS, et al. Bcl2 and P53 expression in clinically localized prostate cancer predict response to external beam radiotherapy. *Urol.* 1999;162:12-16.
52. Apakama L, et al. Bcl2 overexpression combined with P53 protein accumulation correlates with hormone refractory prostate cancer. *Br J Cancer.* 1996;74:1258-1262.
53. Mockey T, et al. Bcl2-Bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. *Urol.* 1998;52(6):1085-1090.
54. Catz SD, Johnson J. Transcriptional regulation of Bcl2 by NFkB and its significance in prostate cancer. *Oncogene.* 1 Nov 2001;20(50):7342-7351.
55. Fanidi A, et al. Cooperative interreaction between C-Myc and Bcl2 proto-oncogene. *Nature (London).* 1992;359:554-556.
56. Altieri DC. Survivin versatile modulation of cell division and apoptosis in cancer. *Oncogene.* 2003;22:8581-8584.
57. Devereaux QL, Reed JC. IAP family proteins. Suppressor of apoptosis. *Genes Dev.* 1999;13:239-2525.
58. Ambrosini C, et al. A novel anti-apoptosis gene survivin in cancer and lymphoma. *Nat Med.* 1997;3:917-921.
59. Jaiswal PK, et al. Survivin a molecular biomarker in cancer. *Indian J Med Res.* 2015 April;141(4):389-397.
60. Xiaoyaon C, et al. Survivin a potential prognostic marker and chemotherapeutic target for colorectal cancer. *Ir J Med Sci.* 2010;179(3):327-335.
61. Lens SM, et al. The case of survivin as mitotic regulator. *Curr Opin.Cell Biol.* 2006;18:612-22.
62. Li F, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. *Nature.* 1998; 396(50):80- 4.
63. Shin S, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspases 3 and 7. *Biochemistry.* January 2001;40(4):1117-23.
64. Marasawa H, et al. HBXIP functions as a cofactor of survivin in apoptosis suppression. *Embo J.* 2003;22:2729-40.
65. Adida C. et al. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. *Am J Pathol.* 1998:152:43-49.
66. Shahrokh F, et al. Survivin expression is associate with features of biologically aggressive prostate carcinoma. *Cancer.* February 15, 2004;100(4).
67. Swana HS, et al. Tumor content of the anti-apoptotic molecule survivin and recurrence of bladder cancer. *New Engl J Med.* 1999;341:452-453.
68. Kato J, et al. Expression of survivin in oesophageal cancer. Correlation with the prognosis and response to chemotherapy. *Int J Cancer.* 2001;95:92-95.
69. McKenzie S, Kypnano N. Apoptosis evasion. The role of survival pathways in prostate cancer progression and therapeutic resistance. *J Cell Biochem.* 2006;97(1):18.

70. Mirza A, et al. Human survivin is negatively regulated by wild type P53 and participates in P53 dependent apoptotic pathways. *Oncogene*. 2002;21:2613-22.
71. Ikeguchi M, et al. Quantitative analysis of expression of Bax, Bcl2, and survivin in cancer cells during cisplatin treatment. *Onco Rep*. 2002 Sept-Oct;9(5):1121-6.
72. Al-Joudi FS, et al. Correlation in survivin expression with P53 and Bcl2 in invasive ductal carcinoma of the breast. *South Asian J Trop Med Public Health*. Sept 2007;38(5).
73. Stewart GD, et al. Analysis of hypoxia associated gene expression in prostate cancer. Lysyl oxidase and glucose transporter -1 expression correlate with Gleason score. *Oncology Reports*. December 2008;20(6):1561-1567.
74. Mousas B, et al. Increased levels of hypoxia in prostate carcinoma correlate significantly with increasing stage and patient age. An Eppendorf PO (2) study. *Cancer*. 2000;89(9):2018-2024.
75. Subarsky P, Hill RP. The hypoxic tumor microenvironment and metastatic progression. *Clin Exp Metastasis*. 2003;20(3):237-50.
76. Luoto KR, et al. Tumor hypoxia as a driving force in genetic instability. *Genome Integr*. 2013:4-5.
77. Dohi T, et al. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. *J Clinical Investigation*. 2004 Oct;114(8):1117-1127.
78. Sharg M, et al. Survivin mediates resistance to anti-androgen therapy in prostate cancer. *Oncogene*. 2005 April 7;24(15):2474-82.
79. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. *Trends Mol Med*. 1 Dec 2001;7(12):542-547.
80. Zhang M, et al. Survivin is a potential mediator of prostate cancer metastasis. *Int J Radiat Oncol Biol Phys*. 2010 Nov 15;78 (4):1095-103.
81. Fernandez JG, et al. Survivin expression promotes VEGF induced tumor angiogenesis via PIK.AKT enhanced B-catherin – TcF-Lef dependent transcription. *Molecular Cancer*. 2014;13:209.
82. Wang P, et al. Survivin promotes glioma angiogenesis through VEGF and BFGF in-vitro and in-vivo. *Mol Carcinog*. 2012;51:586-595.
83. Green MM, et al. Expression of vesicular endothelial growth factor (VEGF) in locally invasive prostate cancer, in prognostic for radiotherapy outcome. *Int J Radiol Oncol Biol Phys*. 2007;67(1):84-90.
84. Trans J, et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. *Proc Natl Acad Sci USA*. 2002;99:4349-54.
85. Riedel F, et al. Vascular Endothelial Growth Factor expression correlates with P53 mutation and angiogenesis in squamous cell carcinoma of the head and neck. *Acta Otolaryngol*. 2000;120:105-11.
86. Zhang M, et al. Survivin mediates resistance to antiandrogen therapy in prostate cancer. *Oncogene*. 2005;24:2474-2482.
87. Shariat SF, et al. Survivin expression is associate with features of biologically aggressive prostate carcinoma. *Cancer*. 2004;100(4):751-757.
88. Pennat M, et al. Targeting survivin in cancer therapy. *Expert Opin Ther Targets*. 2008;12: 463-76.
89. Joudi FS, et al. The effects of chemotherapeutic drugs on the viability, apoptosis and survivin expression in MCF-7 cells. *Acta Histochem Cytochem*. 2005;38:323-30.
90. Kavalueluck F, et al. Expression of survivin, Bcl2, P53 and Bax in breast carcinoma and ductal intraepithelial neoplasia. (Din.1 A ) *J Exp Clin Cancer Res*. 2004;23:105-12.
91. Pisters LL, et al. Evidence that transfer of functional P53 protein results in increasing apoptosis in prostate cancer. *Clin Cancer Res*. 2004;10(8):2587-2593.
92. Garrison JB, Kyprianou N. Novel targeting of apoptosis pathways for prostate cancer therapy. *Curr Cancer Drug Target*. 2004;4(1):85-95.
93. Xisuhen W, Li G. Immunology studies with Zhen Hua. *J New Rem & Clin*. March 2000;49(3).
94. Heberman RB. Possible role of Natural Killer cells and other effector cells in immune surveillance against cancer. *J Invest Dermatol*. 1984;83:137-140.
95. Guo Y, et al. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones. *J Nutr Biochem*. 2007;18(6):408-417.
96. Trudel D, et al. Matrix metalloproteinase 9 is associate with Gleason score in prostate cancer but not with prognosis. *Human Pathol*. 2010;41:1649-701.
97. Szarvas T, et al. Elevated serum matrix metalloproteinase 7 levels predicts poor prognostics after radical prostatectomy. *Int J Cancer*. 2011;128:1486-92.
98. Dorai T, et al. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis and inhibits angiogenesis of LNCap prostate cancer cells in-vivo. *Prostate*. 2001;47:293-303.
99. Bhandarkar SS, Arbser JL. Curcumin as an inhibitor of angiogenesis. *Adv Exp Med Bio*. 2007;595:185-195.
100. Chondhuri T, et al. Curcumin selectively induce apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a P53-dependent manner. *J Biol Chem*. 2005; 208:2059-68.
101. Chendil D, et al. Curcumin confers radiosensitizing effect in prostate cancer cell line Pc3. *Oncogene*. 2004;26:1599-607.
102. Dorai T, et al. Therapeutic potential of curcumin in human prostate cancer. Curcumin induces apoptosis in both androgen-dependent and androgen-independent prostate cancer cells. *Prostate Cancer Prostatic Dis*. 2000;3:84-93.
103. Fujita H et al. Cyclooxygenase-2-promotes prostate cancer progression. *The Prostate*. 17 Oct 2002; DOI.10 1002/pros 10152

104. Fosslien E. Molecular pathology of cyclooxygenase 2 in cancer-induced angiogenesis. *Ann Clin Lab Sc.* Fall 2011;131(4):325-348.
105. Berger G, et al. Matrix metalloproteinase-9- triggers the angiogenic switch during carcinogenesis. *Nat Cell Biol.* 2000 Oct 2;10:737-44.
106. Kim JH, et al. Tumeric (*Curcuma longa*) inhibits inflammatory factor (NF) and NF-KB regulated gene products and induce death receptors leading to suppressed proliferation, induced chemosensitization and suppressed osteoclastogenesis. *Mol Nutr Food Res.* March 2012;56(3):454-456.
107. Lee L, et al. Liposome-encapsulated curcuma, in-vitro and in-vivo effects on proliferation, apoptosis signaling and angiogenesis. *Cancer.* October 2005;104:1322-31.
108. Dupont E, et al. (1997a) Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression. Process of making thereof. USP. No5618925.
109. Dupont E, et al. Antiangiogenic and antimetastatic properties of Neovastat (Ae-941) an orally active extract derived from shark cartilage. *Clinical Exp Metastasis.* 2002;19:145-153.
110. Lee A, Langer R. Shark cartilage contains inhibitors of angiogenesis. *Science.* 1983;221: 1185-1187.
111. Fontenele JB, et al. Anti-inflammatory and analgesics activity of water-soluble fraction from shark cartilage. *Braz J Med Biol Res.* 1996;29:643.
112. Chan GC, et al. The immunomodulatory and anticancer properties of propolis. *Clin Rev Allergy Immunol.* 2013;44:262-273.
113. Orsolic N, et al. Effects of local administration of propolis and its polyphenolic compounds on tumor formation and growth. *Biol Pharma Bull J.* 2005;28:1928-1933.
114. Natarajan K, et al. Caffeic acid phenethyl ester is a potent and specific inhibitor of nuclear transcription factor NF-kappaB. *B Proc Acad Sci USA.* 1996;93:9090-95.
115. Sziliszka E, et al. Ethanolic extract of propolis augments TRAIL-induced apoptotic dead in prostate cancer cells. *Evidence-based Complementary and Alternative Medicine.* 2011.
116. Chuu CP, et al. Caffeic acid phenethyl ester suppress the proliferation of human prostate cancer cells through inhibition of P70S6K and AKT signaling pathway. *Cancer Preventive Research.* 2012;5(5):788-797.
117. Silva-Carvalho P, et al. Anti-tumoral and antiangiogenic activity of Portuguese propolis in-vitro and in-vivo mode. *Journal of Functional Foods.* November 2014.
118. Tolba MF, et al. Caffeic acid phenethyl ester synergistically enhances docetaxel and paclitaxel cytotoxicity in prostate cancer cells. *IUBMB – Life.* 2013;65:716-729.
119. Dantuck AJ, et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. *Clin Cancer Res.* 2006;12(13):4018-4026.
120. Paller CJ, et al. A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. *Prostate Cancer Prostatic Dis.* 2013;16(1):50-55.
121. Ornish D, et al. Intensive Lifestyle changes may affect the progression of prostate cancer. *Journal of Urology.* 2005 Sept;174(3):1065-9